Physician profile
David Mares
NPI 1396770335
$1,332,363.42
in general payments reported to CMS, 2019-2025
42 companies · $228K in 2025
The $228K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234K · 2020: $113K · 2021: $166K · 2022: $160K · 2023: $216K · 2024: $215K · 2025: $228K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $609K · Food and Beverage: $20K · Travel and Lodging: $15K · Honoraria: $10K · Consulting Fee: $4,238 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $609,389.70 |
| Food and Beverage | $20,472.05 |
| Travel and Lodging | $15,083.19 |
| Honoraria | $10,000.00 |
| Consulting Fee | $4,237.50 |
| Education | $186.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $941,653.63 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Grifols USA, LLC | $149,554.92 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Mylan Specialty L.P. | $74,077.40 | 2019-2024 | Yupelri, Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48,938.53 | 2019-2025 | Ofev |
| Regeneron Healthcare Solutions, INC. | $32,904.17 | 2019-2025 | Dupixent |
| Viatris Specialty LLC | $26,535.71 | 2025 | Yupelri |
| Amgen INC. | $21,270.95 | 2022-2025 | Tezspire |
| Verona Pharma, INC. | $10,903.21 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $10,687.72 | 2019-2025 | Xolair |
| Sunovion Pharmaceuticals INC. | $7,309.11 | 2019 | |
| Grifols Shared Services North America, INC. | $2,460.00 | 2023 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $1,693.98 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $565.11 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $509.57 | 2020-2025 | Acthar |
| Insmed, INC. | $384.18 | 2019-2025 | Brinsupri, Arikayce |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mares listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.